As of January 2023, our "Journal of Controversies Obstetrics & Gynecology and Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Maternal serum vasohibin-1 and vasohibin-2 concentrations in pregnant women diagnosed with late fetal growth restriction or small for gestational age fetus
Aims: Vasohibin 1, a member of the vasohibin family, is an inhibitor of angiogenesis, while vasohibin 2 stimulates angiogenesis. Placental expressions of vasohibins and their relationship with preeclampsia have been investigated, but their effects on intrauterine fetal growth are unknown. In this context, we aimed to investigate the concentrations of vasohibin 1 and 2 in the serum of pregnant women diagnosed with late fetal growth restriction (FGR) or small for gestational age (SGA) in the third trimester.
Methods: This prospective non-interventional cohort study was conducted on 81 pregnant women, 26 of whom were diagnosed with late FGR, 28 were SGA, and 27 were healthy controls. Three groups were compared in terms of serum vasohibin 1 and 2 concentrations in the third trimester.
Results: Three groups were similar in terms of demographic characteristics and gestational age at blood sampling for vasohibin 1 and 2 (p < 0.05). The median vasohibin 1 concentration was determined as 1227.41 ng/mL in the late FGR group, 1311.15 ng/mL in the SGA group, and 1391.38 ng/mL in the control group (p = 0.139). The median vasohibin 2 concentration was determined as 11.24 ng/mL in the late FGR group, 11.86 ng/mL in the SGA group, and 14.34 ng/mL in the control group (p = 0.198).
Conclusion: Serum vasohibin 1 and 2 concentrations were found to be similar in pregnant women diagnosed with late FGR and SGA and pregnant women with AGA fetuses. Vasohibin 1 and 2 are involved in the regulation of placental angiogenesis, but their roles in intrauterine fetal growth remain unclear.

1. Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetalgrowth restriction. Am J Obstet Gynecol. 2018;218(2):S745-S761. doi:10.1016/j.ajog.2017.11.577
2. Audette MC, Kingdom JC. Screening for fetal growth restriction andplacental insufficiency. Semin Fetal Neonatal Med. 2018;23(2):119-125.doi: 10.1016/j.siny.2017.11.004
3. Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definitionof fetal growth restriction: a Delphi procedure: Consensus definitionof FGR. Ultrasound Obstet Gynecol. 2016;48(3):333-339. doi: 10.1002/uog.15884
4. Unterscheider J, Daly S, Geary MP, et al. Optimizing the definition ofintrauterine growth restriction: The multicenter prospective PORTOStudy. Am J Obstet Gynecol. 2013;208(4):290.e1-290.e6. doi: 10.1016/j.ajog.2013.02.007
5. Du H, Zhao J, Hai L, Wu J, Yi H, Shi Y. The roles of vasohibin and itsfamily members: beyond angiogenesis modulators. Cancer Biol Ther.2017;18(11):827-832. doi: 10.1080/15384047.2017.1373217
6. Sonoda H, Ohta H, Watanabe K, Yamashita H, Kimura H, Sato Y.Multiple processing forms and their biological activities of a novelangiogenesis inhibitor vasohibin. Biochem Biophys Res Commun.2006;342(2):640-646. doi: 10.1016/j.bbrc.2006.01.185
7. Sato Y, Sonoda H. The vasohibin family: a negative regulatorysystem of angiogenesis genetically programmed in endothelial cells.Arterioscler Thromb Vasc Biol. 2007;27(1):37-41. doi: 10.1161/01.ATV.0000252062.48280.61
8. Sato Y. The vasohibin family: a novel family for angiogenesis regulation.J Biochem. 2013;153(1):5-11. doi:10.1093/jb/mvs128
9. Shimizu K, Watanabe K, Yamashita H, et al. Gene regulation of a novelangiogenesis inhibitor, vasohibin, in endothelial cells. Biochem BiophysRes Commun. 2005;327(3):700-706. doi: 10.1016/j.bbrc.2004.12.073
10. Kimura H, Miyashita H, Suzuki Y, et al. Distinctive localizationand opposed roles of vasohibin-1 and vasohibin-2 in the regulationof angiogenesis. Blood. 2009;113(19):4810-4818. doi: 10.1182/blood-2008-07-170316
11. Suenaga K, Kitahara S, Suzuki Y, et al. Role of the vasohibin family inthe regulation of fetoplacental vascularization and syncytiotrophoblastformation. PLoS One. 2014;9(9):e104728. doi: 10.1371/journal.pone.0104728
12. Lees CC, Stampalija T, Baschat AA, et al. ISUOG practice guidelines:diagnosis and management of small-for-gestational-age fetus and fetalgrowth restriction. Ultrasound Obstet Gynecol. 2020;56(2):298-312. doi:10.1002/uog.22134
13. Reynolds LP, Borowicz PP, Caton JS, Crouse MS, Dahlen CR, WardAK. Developmental programming of fetal growth and development.Vet Clin North Am Food Anim Pract. 2019;35(2):229-247. doi: 10.1016/j.cvfa.2019.02.006
14. Sun C, Groom KM, Oyston C, Chamley LW, Clark AR, James JL. Theplacenta in fetal growth restriction: what is going wrong? Placenta.2020;96:10-18. doi:10.1016/j.placenta.2020.05.003
15. Hu M, Li J, Baker PN, Tong C. Revisiting preeclampsia: a metabolicdisorder of the placenta. FEBS J. 2022;289(2):336-354. doi: 10.1111/febs.15745
16. Dess&igrave; A, Pravettoni C, Cesare Marincola F, Schirru A, Fanos V. Thebiomarkers of fetal growth in intrauterine growth retardation andlarge for gestational age cases: from adipocytokines to a metabolomicall-in-one tool. Expert Rev Proteomics. 2015;12(3):309-316. doi:10.1586/14789450.2015.1034694
17. Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ.Philos Trans R Soc B Biol Sci. 2015;370(1663):20140066. doi: 10.1098/rstb.2014.0066
18. Burton GJ, Charnock-Jones DS, Jauniaux E. Regulation of vasculargrowth and function in the human placenta. Reproduction.2009;138(6):895-902. doi: 10.1530/REP-09-0092
19. Clark D, Smith S, Licence D, Evans A, Charnock-Jones D. Comparisonof expression patterns for placenta growth factor, vascular endothelialgrowth factor (VEGF), VEGF-B and VEGF-C in the human placentathroughout gestation. J Endocrinol. 1998;159(3):459-467. doi: 10.1677/joe.0.1590459
20. Watanabe K, Hasegawa Y, Yamashita H, et al. Vasohibin as anendothelium-derived negative feedback regulator of angiogenesis. JClin Invest. 2004;114(7):898-907. doi: 10.1172/JCI200421152
21. Shibuya T, Watanabe K, Yamashita H, et al. Isolation andcharacterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin.Arterioscler Thromb Vasc Biol. 2006;26(5):1051-1057. doi: 10.1161/01.ATV.0000216747.66660.26
22. Farina A, Morano D, Arcelli D, et al. Gene expression in chorionicvillous samples at 11 weeks of gestation in women who developpreeclampsia later in pregnancy: implications for screening. PrenatDiagn. 2009;29(11):1038-1044. doi: 10.1002/pd.2344
23. Liang Y, Wang F, Chen G, Lu W, Zhang Y. Vasohibin 1, a clinicallyrelevant biomarker, contributes to pre-eclampsia. Int J Clin Pract.2021;75(5):e14017. doi: 10.1111/ijcp.14017
Volume 2, Issue 2, 2024
Page : 24-28